BioCryst (BCRX) announced the appointment of Sandeep Menon as chief research and development officer. Menon joins BioCryst from Alnylam (ALNY), where he served as chief development officer, overseeing global clinical development and safety across a broad portfolio spanning multiple therapeutic areas.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- EOG, GitLab, StoneCo, Cipher, BioCryst Insider Shake-Up
- 3 Best Value Stocks with Over 20% Upside in 2026, According to Analysts
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst price target raised to $22 from $21 at Wedbush
- Brand Risks Emerge in BioCryst’s ORLADEYO Sale to Neopharmed as Fragmented Positioning Threatens Long‑Term Value